Information  X 
Enter a valid email address

Trellus Health PLC (TRLS)

  Print   

Thursday 09 September, 2021

Trellus Health PLC

Notice of Results

RNS Number : 1931L
Trellus Health PLC
09 September 2021
 

Trellus Health plc

("Trellus Health" or the "Company")

 

Notice of Interim Results

 

LONDON, UK. AND NEW YORK, U.S. (9 September 2021). Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, announces that its maiden interim results for the six month period ended 30 June 2021 will be released on Wednesday 22 September 2021.

 

Analyst Briefing

A briefing open to analysts will take place remotely via video conference call on Wednesday 22 September at 1.00pm (BST). If you would like the details of this call please contact Walbrook PR on [email protected].

 

Investor Presentation

Monique Fayad, Chief Executive Officer, Marla Dubinsky, Co-Founder and Salim Hamir, Company Secretary and Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on Wednesday 22 September 2021 at 4.30pm (BST).

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Trellus Health plc via:

 

https://www.investormeetcompany.com/trellus-health-plc/register-investor

 

Investors who already follow Trellus Health plc on the Investor Meet Company platform will automatically be invited.

 

 

For further information please contact:

 

Trellus Health plc

www.trellushealth.com

M onique Fayad , CEO 

Via Walbrook PR

Julian Baines, Chairman

 


 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Jen Boorer /Hannah Woodley

 


 

Walbrook PR Limited

Tel: 020 7933 8780 or  [email protected]

Paul McManus / Sam Allen

Mob: 07980 541 893 / 07502 558 258

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health (LSE: TRLS) is a leading pioneer in resilience-driven care and the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health's digital-first chronic care management solution integrates convenient access to a licensed multidisciplinary care team with a suite of tools for resilience assessment, education and behavior modification, remote monitoring, health maintenance and prevention. Through its TrellusElevate™ connected care platform and companion App, the Company coordinates expert whole-person care, addressing both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.

 

Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver personalised care remotely via telehealth. The Company is initially focused on Inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the proprietary methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. The proprietary methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85 per cent. reduction in unplanned healthcare utilisation (emergency department visits and hospitalisations) which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers.

 

The Company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health's patent-pending GRITTTM resilience assessment and personalized treatment methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS.  For more information on Trellus Health, visit www.trellushealth.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFVLLBFKLXBBQ

a d v e r t i s e m e n t